Metalloproteinases and cancer


The present series of Cancer Metastasis Reviews focuses on metalloproteinases (MPs) and their inhibitors in cancer. These reviews written by recognized leaders in the field focus on the families of matrix metalloproteinases (MMPs) and the a desintegrin and metalloproteinase (ADAMS) and their inhibitors the tissue inhibitors of metalloproteinases (TIMPs). The reviews come in a time when the field of MPs, in particular the MMP field, is at a crossroad. In the last few years, accumulating evidence from experimental models of cancer, knockout mice and proteomics studies has challenged our views on how MMPs function in cancer progression. This challenge has been compounded by the fact that the clinical trials with MMP inhibitors failed to show therapeutic efficacy in cancer patients. All these tribulations are not unique to the MMP field and are clear evidence of the complexities of proteolytic systems and their substrate targets in disease conditions. The present reviews cover some of the most significant advances in the field of MPs and also provide some provocative ideas and views that we hope will promote discussion. The study of the role of MMPs in cancer metastasis has been greatly benefited by the development of animal models and the use of transgenic and knockout mice. The emerging picture is not simple and reveals that the contribution of MMPs to cancer progression is complex. The long-held view that the MMPs as a whole promote cancer metastasis has been disproved by convincing experimental data. Today, the evidence shows that members of the MMP family may promote or inhibit cancer development. Moreover, an individual MMP may act positively (promoting) or negatively (inhibiting) on tumor progression depending, among other

DOI: 10.1007/s10555-006-7885-x

Cite this paper

@article{Fridman2006MetalloproteinasesAC, title={Metalloproteinases and cancer}, author={Rafael Fridman}, journal={Cancer and Metastasis Reviews}, year={2006}, volume={25}, pages={7-8} }